基于网络药理学的黄连解毒汤治疗阿尔兹海默症的作用机制研究

Network pharmacology-based study on intervention mechanism of Huanglian Jiedu decoction in the treatment of Alzheimer's disease

建立黄连解毒汤"药效成分-靶标-通路"之间的关系,探究该方治疗阿尔兹海默症(Alzheimer's disease,AD)的多成分、多靶点和多途径作用机制,为创新药物研究奠定基础。自黄连解毒汤中筛选出已知的17个具有抗AD作用的药效成分,利用Pharm Mapper进行靶标预测,建立"药效成分-靶标蛋白"对应关系;通过Molecule Annotation System(MAS 3.0)数据库对获得的靶标蛋白进行Kyoto Encyclopedia of Genes and Genomes(KEGG)通路注释;利用Cytoscape 3.4.0软件构建"药效成分-靶点-通路"网络图。预测结果表明,黄连解毒汤中17个药效成分的作用靶点共59个,涉及通路47条,其中与AD相关的靶点蛋白共4个,与神经炎症相关的通路共2条。通过"药效成分-靶标-通路"分析可知,黄连解毒汤可能通过清除/减少β淀粉样蛋白、抑制Tau蛋白过度磷酸化、抗炎和免疫活性等多途径对AD具有治疗作用。

This study was designed to explore the ＂multi-components, multi-targets and multi-pathways＂ intervention mechanism of Huanglian Jiedu decoction（HLJDD） in the treatment of Alzheimer＇s disease（AD） by pharmacological network technology, which may establish a foundation for drug development and innovative research. Seventeen active constituents of HLJDD with anti-AD activities were submitted to Pharm Mapper and Molecule Annotation System（MAS 3.0） bioinformatics softwares to predict the target proteins and carry out related KEGG pathways annotation respectively. The network of ＂active compound-target-pathway＂ was constructed and analyzed using the Cytoscape 3.4.0 software. The results suggest that 47 pathways are affected by the 17 active components through 59 target proteins, in which 4 target proteins are related to AD and 2 pathways related to neuroinflammation, respectively. The effect of HLJDD on AD may be dependent on clearing/reducing β-amyloid protein, inhibiting Tau hyperphosphorylation, anti-inflammation and immunoregulation.